Plasma membrane phosphotyrosine, Her2-NEU, and epidermal growth factor receptor in human breast cancer: A comparative study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 6, 1996, Pages 552-557

  Heffelfinger, Sue C ^a   Lower, Elyse E ^a   Miller, Mary Ann ^a   Fenoglio Preiser, Cecilia M ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Epidermal growth factor receptor; Her2 NEU; Phosphotryrosine; Signal transduction; Tyrosine kinase

Indexed keywords

ANTIBODY; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHOTYROSINE; PROTEIN; PROTEIN TYROSINE KINASE; TRANSFORMING GROWTH FACTOR ALPHA; TYROSINE;

ARTICLE; AUTOPHOSPHORYLATION; BREAST CANCER; CELL MEMBRANE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CELL NUCLEUS; CYTOPLASM; EPIDERMAL GROWTH FACTOR; EPITHELIUM; FEMALE; FIXATIVES; FORMALDEHYDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; ONCOGENES; PARAFFIN EMBEDDING; PHOSPHORYLATION; PHOSPHOTYROSINE; PROTEIN-TYROSINE KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TISSUE FIXATION; TUMOR CELLS, CULTURED;

EID: 0029846467     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199612000-00003     Document Type: Article

References (33)

1. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-12.
2. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB related gene in human mammary carcinoma. Science 1985;229:974-6.
3. Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986;45:649-57.
4. Bargmann CI, Weinberg RA. Oncogene activation of the neuencoded receptor protein by point mutation and deletion. EMBO J 1988;7:2043-52.
5. Siegel PM. Dankort DL, Hardy WR, Muller WJ. Novel acti- vating mutations in the neu proto-oneogene involved in induction of mammary tumors. Mol Cell Biol 1994;14:7068-77.
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGauire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
7. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990;8:103-12.
8. Hainsworth PJ, Henderson MA, Stillwell RG, Bennett RC. Comparison of EGFR, c-erbB-2 product and ras p21 immunohistochemistry as prognostic markers in primary breast cancer. Eur J Surg Oncol 1991;17:9-15.
9. Lundy J, Schuss A, Stanick D, McCormack ES, Kramer S, Sorvillo JM. Expression of neu protein, epidermal growth factor receptor, and transforming growth factor alpha in breast cancer. Am J Pathol 1991;138:1527-34.
10. Klijn JGM, Berns PMJJ, Schmitz PIM, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review of 5232 patients. Endocr Rev 1992;13:3-17.
11. Umekita Y, Enokizono N, Sagara Y, et al. Immunohistochemical studies on oncogene products (EGF-R, C-erbB-2) and growth factors (EGF, TGF-a) in human breast cancer: their relationship to oestrogen receptor status, histological grade, mitotic index and nodal status. Virchows Arch [A] 1992;420:345- 51.
12. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl Med 1994;330:1260-6.
13. Drebin JA, Link VC, Greene MI. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene 1988;2:273-7.
14. Drebin JA, Link VC, Greene MI. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 1988;2:387-94.
15. Bacus SS, Stancovski I, Huberman E, et al. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Cancer Res 1992;52:2580-9.
16. DiGiovanna MP, Stern DF. Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor. Cancer Res 1995;55:1946-55.
17. Paik S, King CR, Simpson S, Lippman ME. Quantification of erbB-2/neu levels in tissue. In: Barnes D, Mathers JP, Sato GH, eds. Methods in enzymology: peptide growth factors. New York: Academic Press, 1991:290-300.
18. Lower E, Heffelfinger SC, Miller MA, Fenoglio-Preiser CM. Phosphotyrosine immunoreactivity is a significant prognostic indicator in breast carcinoma patients. Breast Cancer Res Treat 1995;35:277-82.
19. Lau KW, Parley JR, Baylink DJ. Phosphotyrosyl protein phosphatases. Biochem J 1989;257:23-36.
20. Kudlow JE, Cheung CYM, Bjorge JD. Epidermal growth factor stimulates the synthesis of its own receptor in a human breast cancer cell line. J Biol Chem 1986;261:4134-8.
21. Valverius EM, Bates SE, Stampfer MR, et al. Transforming growth factor α production and epidermal growth factor receptor expression in normal and oncogene transformed human mammary epithelial cells. Mol Endocr 1989;3:203-14.
22. Read LD, Keith D, Slamon DJ, Katzenellenbogen BS. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 1990;50:3947-51.
23. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H. ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene 1991;6:137-43.
24. Ciardiello F, Dono R, Kim N, Persico MG, Salomon DS. Expression of cripto, a novel gene of the epidermal growth factor gene family, leads to in vitro transformation of a normal mouse mammary epithelial cell line. Cancer Res 1991;51:1051-4.
25. Peles E, Levy RB, Or E, Ullrich A, Yarden Y. Oncogenic forms of the neu/Her2 tyrosine kinase are permanently coupled to phospholipase Cγ. EMBO J 1991;10:2077-86.
26. Scott GK, Dodson JM, Montgomery PA, et al. p 185HER2 signal transduction in breast cancer cells. J Biol Chem 1991;266:14300-5.
27. Bacus SS, Huberman E, Chin D, et al. A ligand for the erbB- 2 oncogene product (gp30) induces differentiation of human breast cancer cells. Cell Growth Differ 1992;3:401-11.
28. LeJeune S, Leek R, Horak E, Plowman G, Greenall M, Harris AL. Amphiregulin, epidermal growth factor receptor, and estrogen receptor expression in human primary breast cancer. Cancer Res 1993;53:3597-602.
29. Scott GK, Robles R, Park JW, et al. A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol 1993;13:2247-57.
30. Lupu R, Lippman ME. The role of erbB2 signal transduction pathways in human breast cancer. Breast Cancer Res Treat 1993;27:83-93.
31. Kidd KR, Kerns BJM, Dodge RK, Wiener JR. Histochemical staining of protein-tyrosine phosphatase activity in primary human mammary carcinoma: relationship with established prognostic indicators. J Histochem Cytochem 1992;40:729-35.
32. Jallal B, Schlessinger J, Ullrich A. Tyrosine phosphatase inhibition permits analysis of signal transduction complexes in p185HER2/neu-overexpressing human tumor cells. J Biol Chem 1992;267:4357-63.
33. Zhai YF, Beittenmiller H, Wang B, et al. Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene. Cancer Res 1993;53:2272-8.